Tudor Investment Corp ET AL Purchases Shares of 9,360 iRadimed Corporation $IRMD

Tudor Investment Corp ET AL acquired a new position in shares of iRadimed Corporation (NASDAQ:IRMD) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 9,360 shares of the medical equipment provider’s stock, valued at approximately $666,000. Tudor Investment Corp ET AL owned approximately 0.07% of iRadimed as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Ranger Investment Management L.P. increased its stake in iRadimed by 7.4% in the 2nd quarter. Ranger Investment Management L.P. now owns 214,840 shares of the medical equipment provider’s stock worth $12,845,000 after purchasing an additional 14,730 shares in the last quarter. Principal Financial Group Inc. purchased a new stake in iRadimed during the third quarter valued at about $422,000. Geode Capital Management LLC lifted its stake in iRadimed by 6.5% during the second quarter. Geode Capital Management LLC now owns 261,386 shares of the medical equipment provider’s stock valued at $15,630,000 after buying an additional 15,996 shares in the last quarter. Shaker Investments LLC OH boosted its holdings in shares of iRadimed by 18.9% in the third quarter. Shaker Investments LLC OH now owns 63,199 shares of the medical equipment provider’s stock worth $4,497,000 after buying an additional 10,056 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in shares of iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after acquiring an additional 495 shares in the last quarter. 92.34% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at iRadimed

In related news, CEO Roger E. Susi sold 5,000 shares of the stock in a transaction on Monday, March 9th. The stock was sold at an average price of $100.04, for a total transaction of $500,200.00. Following the completion of the sale, the chief executive officer directly owned 2,250,000 shares in the company, valued at approximately $225,090,000. This trade represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 37,500 shares of company stock valued at $3,765,750 over the last 90 days. Corporate insiders own 36.80% of the company’s stock.

iRadimed Price Performance

Shares of IRMD opened at $96.26 on Wednesday. The business’s 50-day moving average is $100.09 and its 200-day moving average is $91.05. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of 55.01 and a beta of 1.12. iRadimed Corporation has a fifty-two week low of $47.48 and a fifty-two week high of $107.90.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 EPS for the quarter, topping the consensus estimate of $0.49 by $0.05. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. The business had revenue of $22.69 million during the quarter, compared to analysts’ expectations of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Equities research analysts expect that iRadimed Corporation will post 1.66 earnings per share for the current fiscal year.

iRadimed Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 6th. Stockholders of record on Monday, February 23rd were issued a dividend of $0.20 per share. The ex-dividend date was Monday, February 23rd. This represents a $0.80 annualized dividend and a dividend yield of 0.8%. This is an increase from iRadimed’s previous quarterly dividend of $0.17. iRadimed’s dividend payout ratio is presently 45.71%.

Analyst Ratings Changes

Several brokerages recently commented on IRMD. Roth Mkm restated a “buy” rating and issued a $120.00 price target on shares of iRadimed in a research report on Tuesday, February 10th. Lake Street Capital reiterated a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research report on Wednesday, February 11th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, iRadimed has a consensus rating of “Moderate Buy” and a consensus target price of $120.00.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.